Immucell (ICCC) Construction in Progress (2011 - 2024)

Immucell's (ICCC) quarterly Construction in Progress came in at $2.3 million in Q4 2024, up 578.1% on a QoQ basis from $341683.0 in Q4 2022.

Immucell (ICCC) Construction in Progress (2011 - 2024) Analysis & Trends

Immucell (ICCC) has 8 years of Construction in Progress data on file, last reported at $2.3 million in Q4 2024.

Quarterly Construction in Progress changed N/A year-over-year to $2.3 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.3 million (changed N/A YoY) and the FY2024 annual result came in at $2.3 million, changed N/A from the prior year.
Construction in Progress improved to $2.3 million in Q4 2024, from $341683.0 in the prior quarter.
In the past five years, Construction in Progress ranged from a high of $2.3 million in Q4 2024 to a low of $341683.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Construction in Progress (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	-
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	152.67 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-
10	Immucell	92.01 Mn	83.15 Mn	2.44 Mn	-

Download Data